Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
NEURON-SPECIFIC ENOLASE IN CEREBROSPINAL-FLUID - A BIOCHEMICAL MARKERFOR NEURONAL DEGENERATION IN DEMENTIA DISORDERS
Autore:
BLENNOW K; WALLIN A; EKMAN R;
Indirizzi:
UNIV GOTEBORG,MOLNDAL HOSP,DEPT CLIN NEUROSCI,NEUROCHEM UNIT S-43180 MOLNDAL SWEDEN GOTHENBURG UNIV,DEPT CLIN NEUROSCI,PSYCHIAT & NEUROCHEM SECT S-41124 GOTHENBURG SWEDEN
Titolo Testata:
Journal of neural transmission. Parkinson's disease and dementia section
fascicolo: 3, volume: 8, anno: 1994,
pagine: 183 - 191
SICI:
0936-3076(1994)8:3<183:NEIC-A>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALZHEIMERS-DISEASE; NERVOUS-SYSTEM; S-100 PROTEIN; NEUROLOGICAL DISORDERS; BRAIN; DAMAGE; LOCALIZATION; ISCHEMIA; SERUM; LEVEL;
Keywords:
ALZHEIMERS DISEASE (AD); BIOCHEMICAL MARKERS; CEREBROSPINAL FLUID (CSF); NEURON-SPECIFIC ENOLASE (NSE);
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
33
Recensione:
Indirizzi per estratti:
Citazione:
K. Blennow et al., "NEURON-SPECIFIC ENOLASE IN CEREBROSPINAL-FLUID - A BIOCHEMICAL MARKERFOR NEURONAL DEGENERATION IN DEMENTIA DISORDERS", Journal of neural transmission. Parkinson's disease and dementia section, 8(3), 1994, pp. 183-191

Abstract

Alzheimer's disease (AD) is the most common disease causing dementia. Today the clinical diagnosis of AD is made by way of exclusion, and no biochemical markers are available to assist the clinical diagnosis. We examined the potential of neuron-specific enolase (NSE) in cerebrospinal fluid (CSF) as a diagnostic marker for AD. NSE was determined with a monoclonal antibody two-site immunoradiometric assay (IRMA) in serum (S) and cerebrospinal fluid (CSF) samples from 45 patients with ''probable Alzheimer's disease (AD)'', 19 patients with vascular dementia (VAD) and 33 age-matched healthy individuals. There was no significant correlation between S-NSE and CSF-NSE, or between CSF/S albumin ratio and CSF-NSE, findings suggesting that the major portion of CSF-NSE is intrathecally produced and that analysis of CSF-NSE alone (without accompanying analysis of serum) is sufficient. CSF-NSE was significantly higher in the AD group (4.7 +/- 2.7 ng/mL; p < 0.0001) and in VAD group (4.5 +/- 2.5 ng/mL; p < 0.001) as compared with the control group(2.2 +/- 1.0 ng/mL), while it did not differ significantly between the AD and the VAD group. These findings suggest that CSF-NSE have a potential as a non-disease specific marker for the neuronal degeneration in dementia disorders.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 00:49:51